121 related articles for article (PubMed ID: 9802389)
1. NPY Y1 antagonists: structure-activity relationships of arginine derivatives and hybrid compounds with arpromidine-like partial structures.
Aiglstorfer I; Uffrecht A; Gessele K; Moser C; Schuster A; Merz S; Malawska B; Bernhardt G; Dove S; Buschauer A
Regul Pept; 1998 Sep; 75-76():9-21. PubMed ID: 9802389
[TBL] [Abstract][Full Text] [Related]
2. Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226.
Wieland HA; Willim KD; Entzeroth M; Wienen W; Rudolf K; Eberlein W; Engel W; Doods HN
J Pharmacol Exp Ther; 1995 Oct; 275(1):143-9. PubMed ID: 7562543
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology and quantitative structure-activity relationships of imidazolylpropylguanidines with mepyramine-like substructures as non-peptide neuropeptide Y Y1 receptor antagonists.
Dove S; Michel MC; Knieps S; Buschauer A
Can J Physiol Pharmacol; 2000 Feb; 78(2):108-15. PubMed ID: 10737673
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships of neuropeptide Y Y1 receptor antagonists related to BIBP 3226.
Aiglstorfer I; Hendrich I; Moser C; Bernhardt G; Dove S; Buschauer A
Bioorg Med Chem Lett; 2000 Jul; 10(14):1597-600. PubMed ID: 10915060
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and neuropeptide Y Y1 receptor antagonistic activity of N,N-disubstituted omega-guanidino- and omega-aminoalkanoic acid amides.
Müller M; Knieps S; Gessele K; Dove S; Bernhardt G; Buschauer A
Arch Pharm (Weinheim); 1997 Nov; 330(11):333-42. PubMed ID: 9431025
[TBL] [Abstract][Full Text] [Related]
6. Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor.
Sautel M; Rudolf K; Wittneben H; Herzog H; Martinez R; Munoz M; Eberlein W; Engel W; Walker P; Beck-Sickinger AG
Mol Pharmacol; 1996 Aug; 50(2):285-92. PubMed ID: 8700135
[TBL] [Abstract][Full Text] [Related]
7. Modular synthesis of non-peptidic bivalent NPY Y1 receptor antagonists.
Weiss S; Keller M; Bernhardt G; Buschauer A; König B
Bioorg Med Chem; 2008 Nov; 16(22):9858-66. PubMed ID: 18851917
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of sympathetic vasoconstriction in pigs in vivo by the neuropeptide Y-Y1 receptor antagonist BIBP 3226.
Lundberg JM; Modin A
Br J Pharmacol; 1995 Dec; 116(7):2971-82. PubMed ID: 8680732
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226.
Doods HN; Wienen W; Entzeroth M; Rudolf K; Eberlein W; Engel W; Wieland HA
J Pharmacol Exp Ther; 1995 Oct; 275(1):136-42. PubMed ID: 7562541
[TBL] [Abstract][Full Text] [Related]
10. N(ω)-Carbamoylation of the Argininamide Moiety: An Avenue to Insurmountable NPY Y1 Receptor Antagonists and a Radiolabeled Selective High-Affinity Molecular Tool ([(3)H]UR-MK299) with Extended Residence Time.
Keller M; Weiss S; Hutzler C; Kuhn KK; Mollereau C; Dukorn S; Schindler L; Bernhardt G; König B; Buschauer A
J Med Chem; 2015 Nov; 58(22):8834-49. PubMed ID: 26466164
[TBL] [Abstract][Full Text] [Related]
11. Discrimination between neuropeptide Y and peptide YY in the rat tail artery by the neuropeptide Y1-selective antagonist, BIBP 3226.
Gicquiaux H; Tschöpl M; Doods HN; Bucher B
Br J Pharmacol; 1996 Dec; 119(7):1313-8. PubMed ID: 8968537
[TBL] [Abstract][Full Text] [Related]
12. BIBP 3226, the first selective neuropeptide Y1 receptor antagonist: a review of its pharmacological properties.
Doods HN; Wieland HA; Engel W; Eberlein W; Willim KD; Entzeroth M; Wienen W; Rudolf K
Regul Pept; 1996 Aug; 65(1):71-7. PubMed ID: 8876038
[TBL] [Abstract][Full Text] [Related]
13. The neuropeptide Y (NPY) Y1 receptor antagonist BIBP 3226: equal effects on vascular responses to exogenous and endogenous NPY in the pig in vivo.
Malmström RE; Balmér KC; Lundberg JM
Br J Pharmacol; 1997 Jun; 121(3):595-603. PubMed ID: 9179405
[TBL] [Abstract][Full Text] [Related]
14. Toward Labeled Argininamide-Type NPY Y1 Receptor Antagonists: Identification of a Favorable Propionylation Site in BIBO3304.
Keller M; Schindler L; Bernhardt G; Buschauer A
Arch Pharm (Weinheim); 2015 Jun; 348(6):390-8. PubMed ID: 25884646
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, structure, and antagonistic properties of des-Asn29[D-Trp28,32]NPY(27-36).
Balasubramaniam A; Zhai W; Tao Z; Huang Y; Fischer JE; Eden P; Taylor JE; Kar L; Samarasinghe SD; Johnson ME
Peptides; 1996; 17(7):1113-8. PubMed ID: 8959744
[TBL] [Abstract][Full Text] [Related]
16. The NPY Y1 receptor antagonist BIBP 3226 blocks NPY induced feeding via a non-specific mechanism.
Morgan DG; Small CJ; Abusnana S; Turton M; Gunn I; Heath M; Rossi M; Goldstone AP; O'Shea D; Meeran K; Ghatei M; Smith DM; Bloom S
Regul Pept; 1998 Sep; 75-76():377-82. PubMed ID: 9802432
[TBL] [Abstract][Full Text] [Related]
17. Characterization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y1 antagonist BIBP 3226.
Abounader R; Villemure JG; Hamel E
Br J Pharmacol; 1995 Oct; 116(4):2245-50. PubMed ID: 8564255
[TBL] [Abstract][Full Text] [Related]
18. Structural basis of ligand binding modes at the neuropeptide Y Y
Yang Z; Han S; Keller M; Kaiser A; Bender BJ; Bosse M; Burkert K; Kögler LM; Wifling D; Bernhardt G; Plank N; Littmann T; Schmidt P; Yi C; Li B; Ye S; Zhang R; Xu B; Larhammar D; Stevens RC; Huster D; Meiler J; Zhao Q; Beck-Sickinger AG; Buschauer A; Wu B
Nature; 2018 Apr; 556(7702):520-524. PubMed ID: 29670288
[TBL] [Abstract][Full Text] [Related]
19. Functional interaction between neuropeptide Y receptors and modulation of calcium channels in the rat hippocampus.
Silva AP; Carvalho AP; Carvalho CM; Malva JO
Neuropharmacology; 2003 Feb; 44(2):282-92. PubMed ID: 12623227
[TBL] [Abstract][Full Text] [Related]
20. Dimeric argininamide-type neuropeptide Y receptor antagonists: chiral discrimination between Y1 and Y4 receptors.
Keller M; Kaske M; Holzammer T; Bernhardt G; Buschauer A
Bioorg Med Chem; 2013 Nov; 21(21):6303-22. PubMed ID: 24074877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
